Arena Pharmaceuticals (ARNA)
$74.68
1.68 (2.20%)
18:44 EST
ARNA Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
3.68B
PE Ratio
-27.16
EPS
-2.75
Volume (Avg. Vol.)
700,538
Day's Range
72.00 - 77.45
52-Week Range
32.95 - 90.19
Dividend & Yield
N/A (N/A)
ARNA Stock Predictions, Articles, and Arena Pharmaceuticals News
- From InvestorPlace
- From the Web
8 Biotech Stocks to Watch After the Q2 Earnings Season
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
5 Clinical-Stage Biotech Stocks to Buy
There are plenty of potential in clinical-stage biotech stocks. Here are five with some wonderful catalysts.
Don’t Get Trapped by All the Hype Surrounding Cronos Stock
The big rally from Cronos Group stock has stalled, but too many investors are certain it's just a breather before another leg higher.
6 Stocks Set for Monster Growth in 2019
Looking for stocks to buy now? These six companies are among the best stocks to invest in for their immaculate record from the Street's top analysts. Here's why:
Why Arena Pharmaceuticals Stock Is Soaring Today
Arena Pharmaceuticals stock was soaring Thursday on news of a license deal with United Therapeutics (UTHR) for ralinepag.
Intercept Pharmaceuticals Inc (ICPT) Stock Dives on Drug Warning
Intercept Pharmaceuticals (ICPT) stock took a hit on Tuesday following the release of a drug warning concerning its Ocaliva.
3 Stocks to Watch on Tuesday: Snap Inc (SNAP), Barracuda Networks Inc (CUDA) and Arena Pharmaceuticals, Inc. (ARNA)
Snap (SNAP) continues slumping below its IPO price Tuesday and Arena Pharmaceuticals (ARNA) rockets ahead on trial data, while Barracuda Networks (CUDA) slides on earnings.
5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here's why VVUS stock is a must
3 Stocks to Watch on Wednesday: Bank of America Corp (BAC), Arena Pharmaceuticals, Inc. (ARNA) and Fogo De Chao Inc (FOGO)
Bank of America (BAC) anxiously awaits a Fed decision on Wednesday, Arena Pharmaceuticals (ARNA) rockets higher and Fogo de Chao (FOGO) carves out some gains.
26 Biotechnology Stocks to Sell Now
The ratings of 26 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
23 Biotechnology Stocks to Sell Now
The overall ratings of 23 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
22 Biotechnology Stocks to Sell Now
This week, 22 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
19 Biotechnology Stocks to Sell Now
The overall ratings of 19 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
3 Stocks to Watch on Friday: Arena Pharmaceuticals, Inc. (ARNA), Micron Technology, Inc. (MU) and Tesla Motors Inc (TSLA)
Tesla (TSLA) shares fell on a self-driving accident, Arena Pharmaceuticals (ARNA) will cut more than half its workforce and Micron (MU) misses revenue estimates.
Hottest Manufacturing Stocks Now – SID BDSI DGLY SPU
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
A Look at My Most Prescient Stock Picks for 2015
Finding the best stocks to buy is a never-ending quest. Looking back on my 2015 predictions, I found a handful of really good ones.
Hottest Healthcare Stocks Now – ISRG MD FOLD ALXN
Healthcare stocks finished down on Wall Street today, down 0.4%.
Hottest Healthcare Stocks Now – ELGX RGEN MASI AMED
Healthcare stocks finished up 0.2% on Wall Street today.
Hottest Healthcare Stocks Now – PTCT CELG ARNA CLDX
Healthcare stocks rose 0.7% on Wall Street so far on Wednesday.
Biggest Movers in Healthcare Stocks Now – ZLTQ EW ICLR HALO
Healthcare stocks rose broadly on Wall Street on Monday, with the sector seeing an overall increase of 0.9%.

Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
Buy